Low tumor interleukin-1ß expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study S. Safi; J. Krzykalla; H. Hoffmann; A. Benner; H. Bischoff; M. Eichhorn; M. Kriegsmann; I. Poschke; F. Stögbauer; L. Umansky; C. Mogler; W. Weichert; H. Winter; P. Beckhove; T. Muley;

Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel A. Araújo; A. Barroso; B. Parente; C. Travancinha; E. Teixeira; F. Martelo; G. Fernandes; G. Paupério; H. Queiroga; I. Duarte; J.D. da Costa; M. Soares; P. Borralho; P. Costa; P. Chinita; T. Almodôvar; F. Barata;

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study F. Barata; H. Queiroga; E. Teixeira; T. Almodovar; M. Soares; B. Parente; J.C. Mellidez; P. Alves; A. Antunes;